** Shares of drugmaker Bristol Myers Squibb BMY.N fall 6.8% to $46.41 after the bell
** BMY says its drug Cobenfy failed to show to statistically significant difference compared to placebo in a late-stage trial studying it as an add-on treatment for schizophrenia
** In September, the U.S. Food and Drug Administration approved the drug, making it the first new type of antipsychotic medicine in decades
** BMY had obtained drug Cobenfy, also known as KarXT, through its $14 billion takeover of Karuna Therapeutics in 2023
** So far this year, BMY stock down about 12%, as of last close
(Reporting by Savyata Mishra in Bengaluru)
((Savyata.Mishra@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。